| Name | (S,R,S)-AHPC-C6-PEG3-C4-Cl |
| Description | (S,R,S)-AHPC-C6-PEG3-C4-Cl is a small molecule HaloPROTAC incorporating the (S,R,S)-AHPC based VHL ligand and a 3-unit PEG linker, capable of inducing the degradation of GFP-HaloTag7 in cell-based assays[1]. |
| In vitro | The chemical compound '(S,R,S)-AHPC-C6-PEG3-C4-Cl' utilizes the cereblon ligand[1] and features a 6-2-2-6 linker, incorporating both hydrophobic and hydrophilic elements to achieve a balanced hydrophilicity/hydrophobicity in the resultant compounds. This compound forms the basis for developing PROTACs aimed at degrading the oncogenic tyrosine kinase BCR-ABL. It is engineered to attach to potent TKIs, specifically bosutinib and dasatinib, facilitating the degradation of c-ABL and BCR-ABL by exploiting either CRBN or VHL E3 ubiquitin ligase mechanisms[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (133.08 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween-80+45% Saline : 3.3 mg/mL (4.39 mM), Sonication is recommeded.
|
| Keywords | VHL | AHPC-C6-PEG3-C4-Cl | (S,R,S)-AHPC-C-6-PEG3-C4-Cl | (S,R,S)AHPCC6PEG3C4Cl | (S,R,S) AHPC C6 PEG3 C4 Cl |
| Inhibitors Related | Pomalidomide-PEG4-Ph-NH2 | Thalidomide-O-amido-PEG2-C2-NH2 TFA | (S,R,S)-AHPC-PEG2-NH2 hydrochloride | Pomalidomide 4'-alkylC3-acid | Thalidomide-O-amido-C6-NH2 TFA | Thalidomide-O-amido-C6-NH2 hydrochloride | Pomalidomide-C2-acid | Thalidomide-propargyl | (S,R,S)-AHPC-PEG3-N3 | Pomalidomide 4'-PEG3-azide | Thalidomide-O-C6-NH2 hydrochloride | Thalidomide-O-amido-C4-NH2 TFA |
United States
